Deborah Charych, Ph.D.Advisor and Co-founder at RayzeBio, Inc.
Dr. Deborah Charych is a Founder and the Chief Technology Officer (CTO) of RayzeBio, Inc, an oncology company focused on targeted delivery of radionuclides. Deborah led the scientific strategy for RayzeBio leading to successful Series A financing and launch in August, 2020 and Series B round in October 2020. Prior to launching RayzeBio, Deborah held a number of scientific leadership positions in biotech, focused on translational drug development. At Nektar Therapeutics, she conceived of and led the pre-clinical and early clinical development of an Immuno-Oncology pipeline, starting with NKTR-214, a next-generation IL-2 receptor agonist, currently in several pivotal Phase 3 oncology trials and later an IL-15 receptor agonist and TLR 7/8 agonist. At FivePrime Therapeutics, Deborah led a team that contributed to the clinical development of novel biologics for pan-FGF and CSF1 inhibition for oncology. While at Chiron Corporation she initiated and led a large proteomics effort to guide oncology target discovery, including the discovery of peptide-mimetic binders ('peptoids'). At Lawrence Berkeley National Laboratory, she assumed an academic leadership role as a tenured Principal Investigator, focusing on new biomaterials. Deborah’s formal education is in Chemistry, earning a PhD from University of California at Berkeley and a B.S. in Chemistry from Carnegie-Mellon University, Pittsburgh, PA where she also learned to fly small airplanes.